Millipore Acquires Rights to Disposable Manufacturing Technology for Biopharmaceutical Production
Millipore Corporation announced it has acquired rights to new technology that enables the sterile filling of biopharmaceutical drugs in a closed, disposable system. The technology was licensed on an exclusive basis for biopharmaceutical applications from Filvek, LLC of Springfield, Vermont. Terms of the deal were not disclosed. Systems based on the new technology are expected to be in testing at customer sites within the next six months.
Susan Vogt, President of Millipore's Biopharmaceutical Division, noted: "This strategic licensing transaction extends our offering to biotech and pharmaceutical customers, and addresses the emerging disposable manufacturing market. It fits into our overall goal of providing complete purification solutions to our customers."
Mark Tanny, President of Filvek, said: "Millipore has the global infrastructure and reputation to accelerate the adoption of our disposable filling technology, and we're very pleased to be working with them. Millipore's disposable sterilizing filters fit right into the new system."
Final filling is that part of drug production where bulk formulated drugs are dispensed into individual vials, ampoules or syringes. This final filling operation needs to be fast, sterile, robust, and accurate in terms of volumes dispensed. With a system based on the new technology, customers can fill solutions while minimizing disassembly, cleaning, sterilizing and re-assembly typical with current methods of final filling.
Stephen Tingley, Millipore's Biopharmaceutical Marketing Manager, noted: "There are labor and cost advantages to this new filling technology, as well as quality advantages in terms of reducing the possibility of cross-contamination. The new technology has an innovative approach to accurately dispensing drugs into each container, and can be easily retrofitted into existing filling lines."
Quelle: Millipore Corp.